Immunocore's Tebentafusp Sole Winner In EU Fast-Track Stakes In June

European Medicines Agency's CHMP Rejected Four Out Of Five Requests

If Immuncore's tebentafusp is fast-tracked all the way through the centralized procedure at the EMA, it could be approved a few months earlier than it otherwise would be.

The EMA will fast track its review of advanced uveal melanoma drug tebentafusp. • Source: Alamy

Immunocore's investigational immunotherapy and lead drug candidate, tebentafusp, will be fast-tracked through the EU review process when the company files for approval. Tebentafusp is a potential treatment for patients with previously untreated metastatic uveal melanoma, a rare and aggressive cancer of the eye.

Immunocore, Ltd.'s accelerated assessment request was the only one of five such applications that was granted at the June...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography